John Robertson
Addiction Psychiatry · Knoxville, TNNPI 1407840481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 820 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations.
Across 820 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$973
- Neurocrine Biosciences, Inc.$920
- plus $7K from 31 others
What the payments were for
- Food & beverage$14,063100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$102
How this compares
Too few addiction psychiatry providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 19 | $56,982 |
| VraylarCariprazine Hcl | 42 | $54,727 |
| TopamaxTopiramate | 12 | $21,136 |
| TrileptalOxcarbazepine | 12 | $12,232 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,889 |
| Aripiprazole | 176 | $11,754 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $10,383 |
| Lurasidone Hcl | 43 | $9,659 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 92 | $6,500 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $6,282 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $5,517 |
| Clozapine | 130 | $4,335 |
| Quetiapine Fumarate | 214 | $4,249 |
| Lamotrigine | 193 | $3,285 |
| Bupropion XlBupropion Hcl | 103 | $2,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,441 | $56,98219 claims |
| AbbVieVraylar | $973 | $54,72742 claims |
| Axsome Therapeutics, Inc.Auvelity | $454 | $11,88912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $146 | $10,38327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Knoxville
- Seth ThompsonJohnson City$527
- Lalitha VaddadiMemphis$427
- Leiberh DiazMemphis$386
- Michael PattersonBartlett$292
- Howard BurleyNashville$111
- Majd AlsayedNashville$89
- Mariah SmithNashville$29
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.